• Molecular NameMicafungin
  • SynonymFK-463; micafungin
  • Weight1270.29
  • Drugbank_IDDB01141
  • ACS_NO235114-32-6
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyAn echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.85
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmVia catechol-O-methyltransferase pathway
  • Half life11~17 h
  • Excretion40% feces, <15% urine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=125mg/kg (Intravenous)
  • LD50 (mouse)N/A